Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Wright Christopher I

Gaffin David Joseph

Hopkinson Craig C.

Parisi Samuel Joseph

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Venu

Trader, Author, Orophile, Technical Analysis Multiple Timeframes https://t.co/E4cQoecQva Only Price Pays®  Maximum Trading Gains w/⚓VWAP https://t.co/4RBYa3EFPj

Brian Shannon, CMT

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Alkermes Plc (ALKS) Stock Price, Analysis & Trade Signals